Taro receives final approval for mometasone furoate lotion

By Elaine Rigoli

Tampa, Fla., March 15 - Taro Pharmaceutical Industries Ltd. announced Wednesday that Taro Pharmaceuticals U.S.A., Inc., its U.S. affiliate, has received final approval from the Food and Drug Administration for its abbreviated New Drug Application for mometasone furoate topical solution USP, 0.1%.

Taro's mometasone lotion is a prescription topical corticosteroid product used primarily for the relief of inflammatory skin conditions.

The Taro product is bioequivalent to Schering-Plough's Elocon lotion, according to a company news release.

According to industry sources, annual U.S. sales of mometasone lotion products are about $9.6 million.

Taro had received tentative approval of its abbreviated NDA for this product in December 2004. Taro USA also has abbreviated NDA approvals for mometasone furoate ointment USP, 0.1% and mometasone furoate cream USP, 0.1%.

Taro Pharmaceutical is a multinational, science-based pharmaceutical company located in Hawthorne, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.